# US 6,730,065 B1 · Night vision composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,065 B1
- Document ID: US6730065B1
- Status: Granted
- Kind: B1
- Application number: 09/675,988
- Filed: 2000-09-29
- Granted: 2004-05-04
- Earliest claimed: 2000-09-29
- Assignees: Ocularis Pharma, LLC
- Inventors: Gerald Horn
- Web page: https://patentgrep.com/patent/US6730065B1

## CPC

- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for optimizing pupil size in individuals suffering from excessive pupillary dilation in dim light as well as through medication is disclosed. Alpha 1 antagonist is applied in an eye drop formulation to the eye, resulting in reduced pupil size in dim light, but less reduction in pupil size in bright light.

## Claims

### Claim 1

A method of treatment, comprising:
subjecting the eye of a patient to refractive surgery;
allowing the eye of the patient to recover; and
administering to the patient a formulation comprising an imidazoline wherein the formulation is a liquid formulation applied directly to the eye of the patient, and wherein the formulation is capable of contracting a pupil of an eye of the patient so that the pupil is twice the size or less in dim light as compared to its size in bright light.

### Claim 2 (depends on 1)

The method of claim 1, wherein the formulation is applied with an eye dropper.

### Claim 3 (depends on 1)

The method of claim 1, wherein the refractive surgery is a surgical means selected from the group consisting of incision, laser ablation, and prosthesis implantation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the formulation further comprises an aqueous solvent.

### Claim 5 (depends on 4)

The method of claim 4, wherein the imidazoline comprises phentolamine.

### Claim 6 (depends on 4)

The method of claim 4, wherein the imidazoline is present in a concentration in a range of from about 0.01 milligrams per cubic centimeter of solvent to about 50 milligrams per cubic centimeter of solvent and wherein the solvent comprises an ophthalmic artificial tear solution.

### Claim 7 (depends on 1)

The method of claim 1, wherein the patient suffers from excessively large pupils in dim light.

### Claim 8 (depends on 1)

The method of claim 1, wherein the patient suffers from poor quality of vision.

### Claim 9 (depends on 1)

The method of claim 1, wherein the eye is of the patient undergoing medication that results in dilation of the pupil diameter.

### Claim 10 (depends on 1)

The method of claim 1, wherein the eye is of the patient that is naturally excessively dilated as a result of response to dimming of light.

### Claim 11

A method of treatment, comprising:
subjecting the eye of a patient to refractive surgery;
allowing the eye of the patient to recover; and
administering to the patient a formulation comprising an alkylating agent wherein the formulation is a liquid formulation applied directly to the eye of the patient, and wherein the formulation is capable of contracting a pupil of the eye of the patient so that the pupil is twice the size of less in dim light as compared to its size in bright light.

### Claim 12 (depends on 11)

The method of claim 11, wherein the formulation is applied with an eye dropper.

### Claim 13 (depends on 11)

The method of claim 11, wherein the refractive surgery is a surgical means selected from the group consisting of incision, laser ablation, and prosthesis implantation.

### Claim 14 (depends on 11)

The method of claim 11, wherein the formulation further comprises an aqueous solvent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the alkylating agent comprises phenoxybenzamine.

### Claim 16 (depends on 15)

The method of claim 15, wherein the alkylating agent is present in a concentration in range from about 0.01 milligrams per cubic centimeter of solvent to about 50 milligrams per cubic centimeter of solvent and wherein the solvent comprises an ophthalmic artificial tear solution.

### Claim 17 (depends on 11)

The method of claim 11, wherein the eye is of the patient which suffers from excessively large pupils in dim light.

### Claim 18 (depends on 11)

The method of claim 11, wherein the patient suffers from poor quality of vision.

### Claim 19 (depends on 11)

The method of claim 11, wherein the eye is of the patient undergoing medication that results in dilation of the pupil diameter.

### Claim 20 (depends on 11)

The method of claim 11, wherein the eye is of the patient that is naturally excessively dilated as a result of response to dimming of light.

### Claim 21

A method of treatment, comprising:
subjecting the eye of a patient to refractive surgery;
allowing the eye of the patient to recover; and
administering to the patient a formulation comprising an alpha 1 antagonist not including a piperazinyl quinazoline wherein the formulation is a liquid formulation applied directly to the eye of the patient, and wherein the formulation is capable of contracting a pupil of an eye of the patient so that the pupil is twice the size or less in dim light as compared to its size in bright light.

### Claim 22 (depends on 21)

The method of claim 21, wherein the formulation is applied with an eye dropper.

### Claim 23 (depends on 21)

The method of claim 21, wherein the refractive surgery is a surgical means selected from the group consisting of incision, laser ablation, and prosthesis implantation.

### Claim 24 (depends on 21)

The method of claim 21, wherein the formulation further comprises an aqueous solvent.

### Claim 25 (depends on 21)

The method of claim 21, wherein the alpha 1 antagonist is present in a concentration in a range of from about 0.01 milligrams per cubic centimeter of solvent to about 50 milligrams per cubic centimeter of solvent and wherein the solvent comprises an ophthalmic artificial tear solution.

### Claim 26 (depends on 21)

The method of claim 21, wherein the patient suffers from excessively large pupils in dim light.

### Claim 27 (depends on 21)

The method of claim 21, wherein the patient suffers from poor quality of vision.

### Claim 28 (depends on 21)

The method of claim 21, wherein the eye is of the patient undergoing medication that results in dilation of the pupil diameter.

### Claim 29 (depends on 21)

The method of claim 21, wherein the eye is of the patient that is naturally excessively dilated as a result of response to dimming of light.
